ATRA Atara Biotherapeutics Inc.

11.5
+0.26  (+2%)
Previous Close 11.24
Open 11.28
Price To Book 2.68
Market Cap 677,948,518
Shares 58,952,045
Volume 2,152,260
Short Ratio
Av. Daily Volume 1,491,502
Stock charts supplied by TradingView

NewsSee all news

  1. Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid

  2. Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress

    Sustained Disability Improvements Seen at Six Months Were Maintained at 12 Months with ATA188 Potential Therapeutic Response with ATA188 Supports Role of Epstein-Barr Virus (EBV) in Pathogenesis of MS Conference

  3. Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress

    Company to Host Live Conference Call and Webcast to Review Data Presentation on May 26, 2020 at 8:00 a.m. EDT/2:00 p.m. CEST Atara Resuming Enrollment in the Phase 1b Study After Brief COVID-19-Related Pause Atara

  4. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors,

  5. Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020

    First published data with novel 1XX CAR signaling and programmed death-1 (PD-1) dominant negative receptor (DNR) checkpoint inhibition technologies Evidence of preclinical safety, improved functional characteristics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data presented at EAN with abstract released May 22, 2020.
ATA188
Multiple sclerosis
BLA filing due 2H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
BLA filing due 2H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 enrolment completed - noted February 27, 2020.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 2 trial to be initiated 2H 2020.
ATA 129
Epstein-Barr virus + other various cancers

Latest News

  1. Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid

  2. Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress

    Sustained Disability Improvements Seen at Six Months Were Maintained at 12 Months with ATA188 Potential Therapeutic Response with ATA188 Supports Role of Epstein-Barr Virus (EBV) in Pathogenesis of MS Conference

  3. Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress

    Company to Host Live Conference Call and Webcast to Review Data Presentation on May 26, 2020 at 8:00 a.m. EDT/2:00 p.m. CEST Atara Resuming Enrollment in the Phase 1b Study After Brief COVID-19-Related Pause Atara

  4. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors,

  5. Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020

    First published data with novel 1XX CAR signaling and programmed death-1 (PD-1) dominant negative receptor (DNR) checkpoint inhibition technologies Evidence of preclinical safety, improved functional characteristics

  6. Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid

  7. Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid

  8. Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress

    — Company to host conference call today at 4:30 p.m. EDT — Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative

  9. Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020

    Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer,

  10. Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the

  11. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant

  12. ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

  13. Company Profile for Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's technology platform leverages

  14. Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update

  15. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  16. Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  17. Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  18. Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  19. Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

    61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study Tab-cel® was generally well-tolerated in all

  20. Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  21. Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  22. Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

    26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara's ongoing tab‑cel® Phase 3 studiesAn

  23. Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  24. Atara Biotherapeutics Announces Executive Departures

    SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

  25. Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference

  26. Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019, at

  27. Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with